High resolution structures of HIV-1 RT from four RT–inhibitor complexes

  title={High resolution structures of HIV-1 RT from four RT–inhibitor complexes},
  author={Jingshan Ren and Robert Esnouf and Elspeth F. Garman and Donald O. Somers and C. K. Ross and Ian Kirby and James Keeling and Graham Darby and Yvonne Jones and David I. Stuart and David K. Stammers},
  journal={Nature Structural Biology},
We have determined the structures of four complexes of HIV-1 reverse transcriptase with non-nucleoside inhibitors, three fully refined at high resolution. The highest resolution structure is of the RT-nevirapine complex which has an R-factor of 0.186 and a root-mean-square bond length deviation of 0.015 Å for all data to 2.2 Å. The structures reveal a common mode of binding for these chemically diverse compounds. The common features of binding are largely hydrophobic interactions and arise from… Expand
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design
This analysis suggests that reducing the solvent content, increasing lattice contacts, and stabilizing the internal low-energy conformations of RT are critical for the growth of crystals that diffract to high resolution. Expand
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations
The crystal structures of TMC278 in complexes with the double mutant K103N/Y181C and L100I/K103N HIV-1 RTs demonstrated that TMC 278 adapts to bind mutant RTs, providing a better understanding of how the flexibility of an inhibitor can compensate for drug-resistance mutations. Expand
Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors
These high-resolution structures illustrate the molecular details of the extensive hydrophobic interactions and the network of main chain hydrogen bonds formed between the NNRTIs and the RT inhibitor-binding pocket, and provide valuable insights into the favorable structural features that can be employed for designing NN RTIs that are broadly active against drug-resistant HIV-1 variants. Expand
HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors
A background on structure-function relationships of HIV-1 RNase H is provided, as well as an outline of current attempts to develop novel, potent chemotherapeutics against a difficult drug target. Expand
Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H.
The characterization of the detailed binding mechanisms of RNH active-site inhibitors, YLC2-155 and ZW566, that bind to the RNH domain through divalent metal ions is described, using NMR, molecular docking, and quantum mechanical calculations. Expand
Targeting structural flexibility in HIV-1 protease inhibitor binding.
HIV-1 protease remains an important anti-AIDS drug target, and it has been suggested that binding of inhibitors in allosteric sites might affect protease flexibility and disrupt its function. Expand
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.
Sub substituted DHBNH derivatives that interact with the NNRTI-binding pocket inhibit both the polymerase and RNH activities of RT and inhibit the initiation of RNA-primed DNA synthesis. Expand
Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures.
Clustering of 99 available X-ray crystal structures of HIV-1 reverse transcriptase (RT) at the flexible non-nucleoside inhibitor binding pocket (NNIBP) provides information about features of theExpand
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
The combined use of structural biology and biochemical approaches has led to the discovery of novel mechanisms of drug resistance and has contributed to the design of new drugs with improved potency and ability to suppress multi-drug resistant strains. Expand
HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
The application of the Autodock program is reported assessing its usability through reproduction of 41 NNRTI experimental bound conformations to gain insight on the mode of action of new anti-HIV agents active against both wild-type and resistant strains. Expand